Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Texas Cardiac Arrhythmia Institute to utilize Odyssey systems

Stereotaxis, Inc., announced that the Texas Cardiac Arrhythmia Institute at St. David's Medical Center in Austin, Texas ordered four Odyssey(TM) systems.

15 Sep 2009

Public health policy should stress on reduction in sodium intake

Reducing sodium intake is a major public health priority that must be acted upon by governments and nongovernmental organizations to improve population health, states an article http://www.cmaj.ca/press/cmaj090361.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

15 Sep 2009

Chinese SFDA approves Abbott's XIENCE V drug eluting stent for treating coronary artery disease

Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.

14 Sep 2009

First patient enrolled in Phase 2b RADAR clinical trial

Regado Biosciences, a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, announced that on September 8, 2009 enrollment of the first patient in a Phase 2b, randomized, partially-blinded, multi-center, active-controlled, dose-ranging study of its lead product candidate, the REG1 anticoagulation system (REG1) was achieved.

11 Sep 2009

Merck update on the status of telcagepant clinical development programs

Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine.

11 Sep 2009

Abbott to acquire Evalve for $410 million

Abbott announced today a definitive agreement to acquire the outstanding equity of Evalve, Inc., the global leader in the development of devices for minimally invasive repair of cardiac mitral valves.

10 Sep 2009

Endothelin research update to be presented at APS' 11th International Conference

Recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of pulmonary arterial hypertension and provides hope for treating other chronic diseases.

10 Sep 2009

U.S patent for Tryton Side Branch Stent System

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced today that a U.S. patent has been awarded for the company’s Tryton Side Branch Stent™ System.

10 Sep 2009

Cardiac Network increases the number of sites for its research study

Cardiac Network, Inc. (PINKSHEETS: CNWI) reported today that it has expanded the number of sites included in its research study support with Southern California Permanente Medical Group.

9 Sep 2009

Research study examines the depression rate in chronic kidney disease patients

One in five patients with chronic kidney disease is depressed, even before beginning long-term dialysis therapy or developing end-stage renal disease, UT Southwestern Medical Center researchers have found.

9 Sep 2009

Exposure to air pollution can cause heart attack

It's well known that measures such as exercise, a healthy diet and not smoking can help reduce high blood pressure, but researchers at the University of Michigan Health System have determined the very air we breathe can be an invisible catalyst to heart disease.

8 Sep 2009

Low HDL-cholesterol and high triglycerides linked to increased risk of CHD

Low levels of high-density lipoprotein cholesterol (HDL-C) and raised triglycerides, affecting millions of patients worldwide, are strongly linked to significantly increased risk of coronary heart disease (CHD) even in patients who achieve or surpass current low density lipoprotein cholesterol (LDL-C) targets.

3 Sep 2009

SYNTAX clinical trial results announced

Boston Scientific Corporation (NYSE: BSX) today announced two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention (PCI) using the TAXUS((R)) Express((R)) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery.

3 Sep 2009

New Technology Showcase highlighting life science technologies to be featured

LifeScience Alley announced today that eight life science organizations from around the United States and Canada will be exhibiting cutting-edge technologies at the association’s Annual Conference on Dec. 9 as part of the New Technology Showcase.

3 Sep 2009

m.pulse system for MCP therapy installed in ten hospitals

Cardiola AG announced today that it has placed its patented m.pulse system in 10 hospitals located in Germany and Switzerland, on the heels of the system’s CE-Mark approval. MCP was previously only available in a clinical setting. Now, m.pulse is the world’s first and only device enabling CAD patients to receive MCP therapy at home.

3 Sep 2009

CT screening for coronary artery calcification can cause radiation-induced cancer

A study based on computer modeling of radiation risk suggests that widespread screening for the buildup of calcium in the arteries using computed tomography scans would lead to an estimated 42 additional radiation-induced cancer cases per 100,000 men and 62 cases per 100,000 women, according to a report in the July 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

2 Sep 2009

$Adult stem cell treatments for severe limb ischemia and refractory coronary ischemia discussed$

Adult stem cell treatments for severe limb ischemia and refractory coronary ischemia discussed

This week TCA Cellular Therapy`s Medical Director Gabriel Lasala, M.D. presents advances in adult stem cell treatments for severe limb ischemia and refractory coronary ischemia at the European Society of Cardiology Congress in Barcelona, Spain.

2 Sep 2009

Cordis enrolls first patient in the CYPRESS clinical study

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that the first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take dual anti-platelet therapy after receiving a CYPHER Sirolimus-eluting Coronary Stent. The procedure was performed by Patrick Flaherty, D.O., Arkansas Heart Hospital in Little Rock, AK.

31 Aug 2009

CLARIFY registry designed to increase knowledge and understanding of CAD was launched in 40 countries

CLARIFY, the largest international registry to ever be carried out in stable coronary artery disease (CAD) patients was launched today in 40 countries, including Canada, at the European Society of Cardiology (ESC) Congress.

31 Aug 2009

Health Net urges Americans to have their blood cholesterol measured

Tomorrow, September 1, marks the start of National Cholesterol Education Month. In support of this educational effort, Health Net, Inc., (NYSE: HNT) is encouraging those who haven't yet done so, to have their blood cholesterol measured and, if it's high, to embark on a cholesterol-lowering program.

31 Aug 2009